Diabetes Treatment
Santa Rosa, CA (PRWEB) April 29, 2006 -– EcoNugenics®, a leading dietary supplement company, announced today that the United States Patent and Trademark Office (USPTO) has issued the company US Patent No. 7,026,302. This important new patent protects the use of modified alginates and modified pectins in treating a wide range of diseases that may be caused or aggravated by heavy metals, environmental toxins or cholesterol. The diseases listed in the patent include arteriosclerosis, atherosclerosis, calcinosis, dermatomyositis, obesity, hypercholesterolemia and diabetes.
EcoNugenics® currently markets two products that are protected by this patent and earlier patents # 6,274,566 and #6,462,029: PectaSol® Modified Citrus Pectin and PectaSol® Chelation Complex. Based on the uses approved in this patent, the company intends to develop and bring to market two new products that will provide nutritional support to individuals with diabetes and high cholesterol.”
“This is excellent news. We are gratified that the US Patent Office has issued this patent, said Isaac Eliaz, MD, L.Ac., President and Founder of EcoNugenics®. “This issuance provides further validation of our strategy and gives us confidence to continue our research and development work on creating a product to address the rising prevalence of diabetes.”
According to the American Diabetes Association 20.8 million children and adults, 7.0% of the entire U.S. population are diabetic. This does not include approximately 41 million people who have pre-diabetes. 1.5 million new cases of diabetes were diagnosed in people aged 20 years or older in 2005. Diabetes can upset the balance between HDL and LDL levels. People with diabetes tend to have low HDL and high triglyceride levels, both of which boost the risk of heart and coronary artery disease.
The American Heart Association estimates that 99.9 million American adults have total blood cholesterol values of 200 mg/dL and higher, and of these about 34.5 million American adults have levels of 240 or above. In adults, total cholesterol levels of 240 mg/dL or higher are considered high risk. Levels from 200 to 239 mg/dL are considered borderline-high risk.
EcoNugenics® was founded in 1995 with a commitment to offering premium dietary supplements based on the best of modern science integrated with the ancient wisdom of traditional and complementary therapies. EcoNugenics® is committed to five basic principles, which include innovation in product formulation, thorough scientific research, ongoing clinical validation, customer education/empowerment and superior quality control. For more information contact Connie St. John at 415-454-2243.
EcoNugenics® currently markets two products that are protected by this patent and earlier patents # 6,274,566 and #6,462,029: PectaSol® Modified Citrus Pectin and PectaSol® Chelation Complex. Based on the uses approved in this patent, the company intends to develop and bring to market two new products that will provide nutritional support to individuals with diabetes and high cholesterol.”
“This is excellent news. We are gratified that the US Patent Office has issued this patent, said Isaac Eliaz, MD, L.Ac., President and Founder of EcoNugenics®. “This issuance provides further validation of our strategy and gives us confidence to continue our research and development work on creating a product to address the rising prevalence of diabetes.”
According to the American Diabetes Association 20.8 million children and adults, 7.0% of the entire U.S. population are diabetic. This does not include approximately 41 million people who have pre-diabetes. 1.5 million new cases of diabetes were diagnosed in people aged 20 years or older in 2005. Diabetes can upset the balance between HDL and LDL levels. People with diabetes tend to have low HDL and high triglyceride levels, both of which boost the risk of heart and coronary artery disease.
The American Heart Association estimates that 99.9 million American adults have total blood cholesterol values of 200 mg/dL and higher, and of these about 34.5 million American adults have levels of 240 or above. In adults, total cholesterol levels of 240 mg/dL or higher are considered high risk. Levels from 200 to 239 mg/dL are considered borderline-high risk.
EcoNugenics® was founded in 1995 with a commitment to offering premium dietary supplements based on the best of modern science integrated with the ancient wisdom of traditional and complementary therapies. EcoNugenics® is committed to five basic principles, which include innovation in product formulation, thorough scientific research, ongoing clinical validation, customer education/empowerment and superior quality control. For more information contact Connie St. John at 415-454-2243.
posted by PeacefulMum at 7:16 AM
<< Home